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Abstract 
Candidiasis or oral candidosis is one of the most common human opportunistic fungal infections of the oral cavity. 
This pathology has a wide variety of treatment which has been studied until these days.  The present study offers 
a literature review on the treatment of oral candidiasis, with the purpose of establish which treatment is the most 
suitable in each case. Searching the 24 latest articles about treatment of candidiasis it concluded that the incidence 
depends on the type of the candidiasis and the virulence of the infection. Although nystatin and amphotericin b were 
the most drugs used locally, fluconazole oral suspension is proving to be a very effective drug in the treatment of 
oral candidiasis. Fluconazole was found to be the drug of choice as a systemic treatment of oral candidiasis. Due 
to its good antifungal properties, its high acceptance of the patient and its efficacy compared with other antifungal 
drugs. But this drug is not always effective, so we need to evaluate and distinguish others like itraconazole or keto-
conazole, in that cases when Candida strains resist to fluconazole.
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Introduction
The incidence of fungal infections has been increasing 
over the last decades, being more prevalent in developed 
countries (1). An increase incidence of the infections is 
associated with some predisposing factors (Table 1) as 
the use of dentures, xerostomia, prolonged therapy with 
antibiotics, local trauma, malnutrition, endocrine disor-
ders, increased longevity of people, among other states 
that diminish the quality of defense of the individual (2). 
Oral candidiasis is one of the most common clinical fea-
tures of those patients infected with the human immuno-
deficiency virus [HIV], this manifestation was seen in 
up to 90% of individuals infected with HIV (3).
Oropharyngeal candidiasis is caused by the genus Can-
dida; it is possible to isolate about 150 species. Many 
of these remain as a commensal micro-organism in hu-
Systemic Local
Hormonal disorders Epithelial changes
Physiological disorders Poor oral hygiene
Endocrine disorders Loss of vertical dimension
Immunologic disorders Poor fitting dentures 
Xerostomia Smoking
Drug therapy 
Alcohol 
Table 1. Predisposing factors.
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tion; Appropriate use of antifungal drugs, evaluating the 
efficacy / toxicity ratio in each case.
When choosing between some treatments it will take 
into account the type of Candida, its clinical pathology 
and if it is enough with a topical treatment or requires a 
more complex systemic type (8), always evaluating the 
ratio efficacy and toxicity (9). The different drugs are 
contained in table 3.
Regular oral and dental hygiene with periodic oral exa-
mination will prevent most cases of oral candidiasis, so 
it is need to make the patient aware of oral hygiene mea-
sures. Oral hygiene involves cleaning the teeth, buccal 
cavity, tongue, and dentures. As well as the use of anti- 
Candida rinses such as Chlorhexidine or Hexetidine, so 
that they can penetrate those areas where the brush does 
not. In addition, the need to remove the dentures at night 
and wash it consciously, leaving it submerged in a disin-
fectant solution like Chlorhexidine (10).
This study provides a literature review of the treatment 
of oral candidiasis and its objectives are to establish ge-
neral guidelines for treatment of oral candidiasis; Assess 
the drug of choice for local treatment of oral candidiasis; 
Assess the systemic treatment for oral candidiasis.
mans, which could act as an opportunistic pathogens of-
ten associated with predisposing factors attributed to the 
organism, thereby causing acute or chronic infections 
(4). The most important of these species is C. albicans, 
which is most commonly isolated from the oral cavity 
and is believed to be more virulent in humans, occurring 
in approximately 50% of the cases of candidiasis.
Clinically there are a number of different types of oral 
candidiasis (Table 2). Therefore the choice of therapy is 
guided by the type of candidiasis.
The diagnosis of oral candidiasis is essentially clinical 
and is based on the recognition of the lesions by the pro-
fessional, which can be confirmed by the microscopic 
identification of Candida (5). The techniques available 
for the isolation of Candida in the oral cavity include 
direct examination or cytological smear, culture of mi-
croorganisms and biopsy which is indicated for cases of 
hiperplasic candidiasis because this type could present 
dysplasias (6).
The treatment of oral candidiasis is based on four fun-
daments (7): making an early and accurate diagnosis of 
the infection; Correcting the predisposing factors or un-
derlying diseases; Evaluating the type of Candida infec-
Table 2. Clinical classification.
Acute Chronic Other lesions
Pseudomembranous Pseudomembranous Angular cheilitis
Erythematous Erythematous Denture-associated erythematous 
Hyperplastic Median rhomboid glossitis
DRUG FORMULATION DOSE ADVERSE EFFECT
Anfotericin b 50mg for infusion 100-200mg/6h Renal, cardiovascular, spinal and neurological
Nystatin Suspension 60ml 
Ointment 30g 
Tablets
4-6ml / 6h 
2 to 4 applications / day 
2 every 8h
Well tolerated.  
 
Uncommon
Nausea, vomiting, gastrointestinal effects
Clotrimazole Gel 1% 
Tablets 10mg
3 times / day 
5 times / day
Occasionally Skin irritation, burning sensation
Miconazole Gel 100mg /6h Uncommon  
Burning, irritation, nausea, diarrhea, 
Ketoconazole Gel 2% 
Tablets 
Suspension 30 or 10cc
3 times/ day
200mg 1-2/day
Nausea, vomiting 
Abdominal pain.
Fluconazole Tablets
Suspension
50 - 100mg/day
10mg/ml
Nausea, vomiting, diarrhea, abdominal pain.
Itraconazole Capsule 100-200mg/day Nausea, vomiting, diarrhea, abdominal pain.
Table 3. Antifungal agents. Vademecum.
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Material and Methods 
A Medline-PubMed search was made using the fo-
llowing key words: “ oral candidiasis” OR “oral candi-
dosis” AND amphotericin, “oral candidiasis” OR “oral 
candidosis” AND nystatine, “oral candidiasis” OR “oral 
candidosis” AND miconazole, “oral candidiasis” OR 
“oral candidosis” AND ketoconazole, “oral candidiasis” 
OR “oral candidosis” AND clotrimazole, “oral candidia-
sis” OR “oral candidosis” AND fluconazole, “oral can-
didiasis” OR “oral candidosis” AND itraconazole, “oral 
candidiasis” OR “oral candidosis” AND treatment, “oral 
candidiasis” OR “oral candidosis” AND “antifungal 
therapy”.The key words were validated by the MeSH 
[Medical Subject Headings] dictionary, with use of the 
boolean operator “AND” to relate them.
The following limits for inclusion of the studies were esta-
blished: articles published from 2000, publications in En-
glish and Spanish and publications of studies in humans. 
All systematic reviews, clinical trials, meta-analysis and 
comparative studies were considered in this review.
A total of 109 articles were identified, of which 30 were 
selected after reading the abstracts. Following analysis 
of the 30 articles, we finally included a total of 24, since 
those publications that did not fit the aims of the present 
study were excluded.
Results
A total of 24 articles were found about antifungal 
treatment, of which 20 were clinical trials, 3 systematic 
reviews and 1 a clinical case (Table 4).
Discussion
Candida infection today is highly prevalent, especia-
lly the increase in carriers of removable dentures and 
poor oral hygiene society. Depending on its virulence, 
location and type of candidiasis there will carry on one 
treatment or another.
First has been supported the use of conservative mea-
sures before starting drug treatment, promoting good 
oral hygiene along with removing the dentures at night, 
thereby it will benefit the removal of the biofilm layer 
generated in the prosthetic surface (11). Dentists should 
also correct the predisposing factors and underlying di-
seases and try to promote the use of oral antiseptic and 
antibacterial rinses such as Chlorhexidine or Hexetidine 
(12). These measures are very effective in patients with 
denture stomatitis (12). It was also found in the study of 
Cross et al. (13) that in patients with good oral hygiene 
the recurrence of candidiasis after 3 years was lower.
Regarding the pharmacological treatment of candidiasis 
can be distinguished between two procedures. Topical 
drugs, which are applied to the affected area and treat 
superficial infections and systemic drugs those that are 
prescribed when the infection is more widespread and 
has not been enough with the topical therapy.
As first choice for local treatment has been for years the 
nystatin at doses of 100 000 IU/ml [5ml 4 times daily] 
and amphotericin b at 50mg [5ml 3 times per day]. This 
choice is because they are poorly absorbed by the in-
testinal tract and therefore most of the antifungal is ex-
creted without undergoing any change, thereby reducing 
hepatotoxicity (14). However, the unpleasant taste and 
prolonged pattern compromise treatment compliance by 
the patient (14-16).
Throughout the years it has been studying the effective-
ness of other drugs like fluconazole oral solution. Many 
authors have focused on evaluating the efficacy and 
safety of fluconazole oral solution for the treatment of 
oropharyngeal candidiasis, especially pseudomembra-
nous type, giving good results, although many studies 
are still needed (14-18).
In a recent study conducted in 19 patients with pseudo-
membranous candidiasis show that fluconazole suspen-
sion in distilled water [2mg/ml] reaches a 95% cure. 
The guideline was to rinse with 5ml of the drug solution 
for 1 minute and then spit it out and repeat this action 
3 times a day for 1 week. Another study which inclu-
ded 36 children with pseudomembranous candidiasis 
showed that fluconazole oral suspension 10mg/ml dose 
gave better results than nystatin. The main problem was 
the poor adherence of the nystatin to the oral mucosa and 
thus the quick ingestion of the suspension, resulting in a 
lower efficiency (14). 
On the other hand, in another study comparing amphote-
ricin b suspension, the fluconazole oral suspension gave 
better results in terms of the eradication of Candida (16). 
The same was corroborated by Taillandier et al. (18), 
which reported that fluconazole oral suspension was as 
effective as amphotericin b, but it was better accepted 
by the patient.
Fluconazole oral suspension is administered in a dosage 
of 10 mg / ml aqueous suspension by administering 5 ml 
daily for 7 or 14 days. Different studies show that it is 
a very effective drug against pseudomembranous candi-
diasis, as it has good adhesion to the surface of the oral 
mucosa and a rapid symptomatic response. It also offers 
the convenience of a one-daily dosing, which may ex-
plain the better patient compliance (14-18). 
Another topic drug widely used is miconazole (19). 
We found it in the form of gel, applying it directly on 
the affected area, at doses of 200-500 mg per day, divi-
ded into 4 times. Despite its good properties it has the 
drawback of possible interaction with other drugs, such 
as warfarin. This is because the antifungal inhibit the en-
zyme cytochrome P-450, which affects the clearance of 
certain drugs (20,21). In addition, this drug is absorbed 
by the intestine, therefore care must be taken when is 
administrated.
It has been introduced in the market an alternative pre-
sentation of miconazole. A one-daily miconazole 50 mg 
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Author/ Year Article Type of article 
/ Sample
Drug Dose Conclusions
Manfredi et 
al. (11) 2006 
In vitro antifungal susceptibility to 
six antifungal agents of 229 
Candida isolates from patients 
with diabetes mellitus
Clinical trial
n=821
Itraconazole 
Miconazole 
Ketoconazole 
Fluconazole 
Anfotericin b
In vitro 
preparations
Those strains that were 
resistant to fluconazole 
also were resistant to 
other drugs.
Koray et al. 
(12)  
2005
Fluconazole and/or hexetidine for 
management of oral candidiasis 
associated with denture-induced 
stomatitis
Clinical trial 
n=61
Hexetidine rinse
Heksoral® 
0,1% 
Fluconazole
Zolax® cap-
sules
2/d
50 mg 1/d
Supports the use of 
antiseptics or 
hexetidine as a first 
choice. 
Conservative i
ntervention
Cross et al.  
(13) 
 2004
Evaluation of the recurrence of 
denture stomatitis and Candida 
colonization in a small group of 
patients who received itraconazole
Clinical trial
n=22
Itraconazole 
rinse
Itraconazole 
capsules
10ml 2/d
100mg 2/d- 
15d
Best  systemic 
itraconazole 
Goins et al. 
(14)  
2002
Comparison of fluconazole and ny-
statin oral suspension for treatment 
of oral candidiasis in infants
Clinical trial 
n=19
n=15
Nystatin sus-
pension
Fluconazole 
suspension 
(Diflucan®)
1ml  
4/d-10d
10mg/ml  
1/d-7d
Fluconazole more 
effective
Epstein  et al. 
(15) 
2002
Fluconazole mouthrinses for oral 
candidiasis in postirradiation 
transplant, and other patients
Clinical trial 
n=19
Fluconazole 
oral solution
5ml 3/d Clinical improvements
Lefebvre et 
al. (16) 
2002
A comparative study of the 
efficacy and safety of fluconazole 
oral suspension and 
amphotericin B oral suspension in 
cancer patients with mucositis
Clinical trial 
n=123
n=120l
Fluconazole 
oral solution 
5ml
Anfotericin b 
oral solution 
5ml
5 ml (50 mg) 
1/d
5ml- 3/d   
7-14 d
Better accepted the 
fluconazole
Sholapurkar 
et al. (17) 
2009
Comparison of efficacy of 
fluconazol mouthrinse and 
clotrimazole mouthpaint in the 
treatment of oral candidiasis
Clinical trial 
n= 27
 
n= 28
Fluconazole 
 
Clotrimazole
5ml  
3/d -14d
mouthpaint 
3/d
Mayor cure rate with 
fluconazole
Taillander et 
al. (18) 
2000
A comparison of fluconazole oral 
suspension and amprotericin B oral 
suspension in older patients with 
oropharyngeal candidosis
Clinical trial
 n=150
n= 155
Fluconazole  
oral suspension
Anfotericin b  
oral suspension
5ml(50mg) 
1/d
5ml- 3/d
No significant 
difference
Isham et al.  
(19) 2010
Antifungal activity of miconazole 
against recent Candida strains
Clinical trial
 n=25
Miconazole In vitro pre-
paration
Miconazole presents 
great inhibitory activity
Pemberton et 
al. (20) 
2004
Miconazole oral gel and drug 
interactions
Clinical case Miconazole gel 125mg/d  3d Decreased the 
clearance of some 
drugs and is absorbed 
by the intestine
Miki et al.  
(21) 
2011
Warfarin and miconazole oral gel 
interactions: analysis and therapy 
recommendations based on clinical 
data and a pharmacokinetic model
Systematic 
review
Miconazole gel 200-400 mg/d Interactions with other 
drugs
Collins et al. 
(22)  
2011
Management of oropharyngeal 
candidiasis with localized oral 
miconazole therapy: efficacy, 
safety, and patient acceptability
Systematic 
review
Miconazole 
buccal tablets 
50mg 1/d Limited systemic 
absorption. Good 
efficacy
Vazquez et al. 
(23)  
2012
Miconazole Mucoadhesive Tablets: 
A Novel Delivery System
Systematic 
review
 n=25
Miconazole 
mucoadhesive 
tablets
50mg 1/d Little systemic 
absorption. 
94.7% efficacy
´Table 4. Summarized articles.
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Author/ Year Article Type of article 
/ Sample
Drug Dose Conclusions
Czerninski et 
al. (24) 
2010
A novel sustained-release 
clotrimazole varnish for local treatment of 
oral candidiasis
Clinical trial 
n= 14
Clotrimazole 
varnish and 
troches
5 times/d Varnish more 
prolonged effect
Oji et al. (25) 
2008
Evaluation and treatment of oral 
candidiasis in HIV/AIDS patient in 
Enugu, Nigeria
Clinical trial 
n=29
Nystatin rinses 
(micostatin®)
Ketoconazole 
tablets 
(nizoral®)
5ml 
4/d- 14d
200mg/ d 
14d
For HIV patients, 
more effective  the 
systemic treatment 
(ketoconazole)
Bensadoun et 
al. (26) 
2008
Comparison of the efficacy and safety of 
miconazole 50-mg mucoadhesive buccal 
tablets with miconazole 500-mg gel in the 
treatment of oropharyngeal 
candidiasis
Clinical trial 
n=141
Miconazole 
mucoadhesive 
tablets 
Miconazole gel
50mg 1/d
 
125mg 4/d
Best treatment plan 
the mucoadhesive 
tablets
Koks et al. 
(27) 
2002
Prognostic factors for the clinical 
effectiveness of fluconazole in the 
treatment of oral candidiasis in HIV-1-
infected individuals
Clinical trial
 n=28
Fluconazole 
capsules 
Diflucan ®
100mg/d Great efficacy of 
fluconazole
Lyon et al. 
(28) 
2006
Correlation between adhesion, 
enzyme production, and 
susceptibility to fluconazole in Candida 
albicans obtained from dentures wearers
Clinical trial
 n=99
Fluconazole In vitro 
preparations
Fluconazole 
reduces erythema 
and cell 
colonization
Oude Lashof 
et al. (29) 
2004
An open multicentre 
comparative study of the efficacy, safety 
and tolerance of fluconazole and 
itraconazole in the treatment of cancer 
patients with oropharyngeal candidiasis
Clinical trial
 n=252
Fluconazole 
capsules
Itraconazole 
capsules
100mg 1/d- 
10d
200mg 1/d- 
15d
Fluconazole better 
result
Kuriyama et 
al. (30) 
2005
In vitro susceptibility of oral 
Candida to seven antifungal agents
Clinical trial
 n=521
Fluconazole 
Itraconazole 
Voriconazole 
Ketoconazole 
Miconazole 
Anfotericin b 
Nystatin
In vitro 
preparations
Some Candida 
species are resistant 
to antifungal drugs
Brito et al. 
(31) 
2011
In vitro antifungal susceptibility of 
Candida spp. Oral isolates from HIV-
positive patients and control individuals
Clinical trial 
n=71 cepas de 
Cándida
Anfotericin b 
Fluconazole 
Flucytosine 
Nystatin 
Ketoconazole
In vitro pre-
parations
Antifungal agents 
showed good 
activity against the 
strains
Ally et al. 
(32) 
2001
A randomized, double-blind, 
double-dummy, multicenter trial of 
voriconazole and fluconazole in the 
treatment of esophageal candidiasis in 
immunocompromised patients
Comparative 
clinical trial 
n=256
Fluconazole 
capsules
Voriconazole 
capsules
200mg 1/d
 
200mg 1/d
Voriconazole was at 
least as effective as 
fluconazole
Khozeimeh et 
al. (33) 
2010
Comparative evaluation of 
ketoconazole tablet and topical 
ketoconazole 2% in orabase in treatment 
of Candida-infected denture stomatitis.
Clinical trial 
n=30
Ketoconazole 
systemic
Ketoconazole 
topical 
Miconazole 
mucoadhesive 
tablet
200mg 1/d
 
2% 2/d
 
50 mg
Miconazole 
mucoadhesive 
tablet used as 
first-line treatment 
because of its good 
tolerance
Van Roey et 
al. (34) 
2004
Comparative efficacy of topical therapy 
with a slow-release mucoadhesive buccal 
tablet containing miconazole nitrate 
versus systemic therapy with 
ketoconazole in HIV-positive patients 
with oropharyngeal candidiasis
Clinical trial 
n=167
n=165
Miconazole 
mucoadhesive 
tablet 
Ketoconazole 
tablets
10mg
 
 
400 mg 
1/d- 14d
Miconazole 
mucoadhesive 
tablets were as 
effective as other 
systemic drugs
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mucoadhesive buccal tablet. It has a limited systemic 
absorption. Its performance is mostly local and it has a 
convenient application form. Patients are instructed to 
apply the rounded side of the 50 mg tablet to the upper 
gum region just above the right or left incisor following 
brushing of teeth in the morning. The tablet should be 
held in place until dissolved (22,23). It has the advanta-
ge of being applied once daily instead 5 times a day with 
clotrimazole (24), and 4 times daily with nystatin (25).
It has been demonstrated the effectiveness of this new 
form of administration in the study of Bensadoun et al. 
(26). 141 patients with head and neck cancer with cli-
nical signs and symptoms of oropharyngeal candidiasis 
received 50 mg mucoadhesive tablets of miconazole 
daily or 125 mg miconazole gel four times per day. Cli-
nical improvement was not significant between the two 
groups, but the mucoadhesive tablets exhibited higher 
salivary concentrations and better tolerance for the pa-
tient. Despite being more expensive, offers an effective, 
safe, and well tolerated topical treatment for oropharyn-
geal candidiasis (22,23,26).
- Systemic treatment:
In spite of knowing the efficacy of the drugs listed abo-
ve, when it comes to a more generalized candidiasis or 
immunocompromised patients, these would not be suffi-
cient. For those cases would have to resort to treatment 
with systemic drugs (25).
Since its introduction, fluconazole has been used to treat 
systemic Candida infections because of its efficacy and 
good tolerability. The appropriate dose is between 50-
100 mg daily (27). Furthermore, when dealing with im-
munocompromised patients, such as those HIV-infected, 
or cancerous, this drug has good effects doubling the 
dose (28,29). Its efficacy has been demonstrated (27). 
The dose was individualized depending on the severity 
and type of candidiasis. Patients with pseudomembra-
nous type started with 100 mg fluconazole daily; patients 
with erythematous variety started with 50 mg fluconazo-
le. Therefore, according to the clinic and the virulence 
of the infection the dose would be titrated, giving good 
results, and increasing the guideline in those cases whe-
re the fungal infection did not decrease (27). 
To support the efficacy of this drug it has been compared 
with other systemic antifungal agents (29). In one ran-
domized study, the efficacy of fluconazole [100mg per 
day for 10 days] and itraconazole [200mg per day for 
15 days] was compared in patients with oropharyngeal 
candidiasis. The results were a clinical and mycologi-
cal improvement of 66% for the first group and 54% for 
those treated with itraconazole. The main conclusion of 
this study is that in patients with oropharyngeal candi-
diasis, fluconazole has a significantly better clinical and 
mycological cure rate compared with itraconazole. The 
failures of itraconazole may be explained by drug in-
teractions and the unpredictable absorption of itracona-
zole capsules. But when fluconazole failed, itraconazole 
was prescribed to these patients, having good results. So 
it is said that it was a good drug for fluconazole-resistant 
Candida strains (29).
As it has been suggested above, it may happen that the 
Candida strains were not susceptible to fluconazole, and 
it has not any effect. In that case it will be used other drugs 
like itraconazole or newest ones as voriconazole (30). 
Keeping always in mind that strains which were resistant 
to fluconazole were also resistant to other drugs (31).
The new triazol antifungal voriconazole [200 mg per 
day] has been shown to be a potent drug. Ally et al. (32) 
compared the efficacy of voriconazole and fluconazole 
in the treatment of esophageal candidiasis. The success 
rate was 98.3% for voriconazole and 95.1% for fluco-
nazole. The results show clearly that voriconazole is at 
least as effective as fluconazole in the treatment of can-
didiasis. It suggests that this new agent may be a use-
ful alternative for fluconazole-resistant Candida strains 
(32). Because of being a new there are little strains resis-
tant to voriconazole. The voriconazole has an important 
role in the treatment of candidiasis (30), although it is 
still not fully established in the market, so many more 
studies and research would be needed.
There have been several studies comparing topical and 
systemic drugs. In a study to treat denture stomatitis have 
been compared the use of ketoconazole tablets [200mg 
daily] with topical ketoconazole [2% twice daily] and 
miconazole mucoadhesive tablets (33). Due to the ad-
verse effects of ketoconazole (31) like nausea, vomiting 
and gastrointestinal problems it has been supported the 
use of other drugs when treating prosthetic candidiasis 
(34). Thus the use of miconazole mucoadhesive tablet 
was established as the drug of first line of defense for 
this type of candidiasis.
General treatment guidelines include after the comple-
tion of an early diagnosis, the correction of predisposing 
factors or underlying diseases and maintaining a good 
oral hygiene. Moreover using antiseptic agents such as 
Chlorhexidine or Hexetidine, as well as removing den-
tures at night. All of that in order to obtain well results in 
the treatment of oral candidiasis as first line of defense, 
continuing the application of antifungal drugs. Begin-
ning with local treatment and keeping up the systemic 
ones for those patients who do not respond to topical 
treatment or in immunocompromised patients.
It has recently been found that fluconazole oral suspen-
sion as a local treatment, at a dose of 2 mg/ml 3 times 
daily or 10 mg /ml once daily, gives good clinical results, 
besides the better patient compliance due to the dosage 
and its pleasant taste. Despite not being currently the 
most widely used locally because it requires further cli-
nical studies. Nowadays the most used drugs remains in 
nystatin solution which contain 100 000 IU / ml [5ml 4 
times daily] and miconazole gel [200 to 500 mg per day 
e582
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divided into 4 doses]. Moreover miconazole mucoad-
hesive tablets [50 mg once daily] which are considered 
effective in the treatment of oropharyngeal candidiasis, 
but their high cost is one of the main problems.
Fluconazole at doses between 50-100 mg per day is the 
systemic drug of choice because it has high efficacy and 
tolerability by the patient. However it is important to 
think about the voriconazole which is as effective as flu-
conazole but is still under study. Also it is need to know 
about other drugs such as itraconazole, which are effec-
tive when Candida strains are resistant to fluconazole.
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